IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1
Top Cited Papers
- 1 October 2004
- journal article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 287 (4), E591-E601
- https://doi.org/10.1152/ajpendo.00073.2004
Abstract
Muscle atrophy results primarily from accelerated protein degradation and is associated with increased expression of two muscle-specific ubiquitin ligases (E3s): atrogin-1 and muscle ring finger 1 (MuRF1). Glucocorticoids are essential for many types of muscle atrophy, and their effects are opposite to those of insulin-like growth factor I (IGF-I) and insulin, which promote growth. In myotubes, dexamethasone (Dex) inhibited growth and enhanced breakdown of long-lived cell proteins, especially myofibrillar proteins (as measured by 3-methylhistidine release), while also increasing atrogin-1 and MuRF1 mRNA. Conversely, IGF-I suppressed protein degradation and prevented the Dex-induced increase in proteolysis. IGF-I rapidly reduced atrogin-1 expression within 1 h by blocking mRNA synthesis without affecting mRNA degradation, whereas IGF-I decreased MuRF1 mRNA slowly. IGF-I and insulin also blocked Dex induction of these E3s and several other atrophy-related genes (“atrogenes”). Changes in overall proteolysis with Dex and IGF-I correlated tightly with changes in atrogin-1 mRNA content, but not with changes in MuRF1 mRNA. IGF-I activates the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, and inhibition of this pathway [but not the calcineurin-nuclear factor of activated T cell (NFAT) or the MEK-ERK pathway] increased proteolysis and atrogin-1 mRNA expression. Thus an important component of growth stimulation by IGF-I, through the PI3K-Akt pathway, is its ability to rapidly suppress transcription of the atrophy-related E3 atrogin-1 and other atrogenes and degradation of myofibrillar proteins.Keywords
This publication has 53 references indexed in Scilit:
- TNF‐α increases ubiquitin‐conjugating activity in skeletal muscle by up‐regulating UbcH2/E220kThe FASEB Journal, 2003
- Signalling pathways that mediate skeletal muscle hypertrophy and atrophyNature, 2003
- Slowing muscle atrophy: putting the brakes on protein breakdownThe Journal of Physiology, 2002
- Regulation of Raf-Akt Cross-talkPublished by Elsevier BV ,2002
- Ubiquitin (UbC) Expression in Muscle Cells Is Increased by Glucocorticoids through a Mechanism Involving Sp1 and MEK1Published by Elsevier BV ,2002
- Identification of Ubiquitin Ligases Required for Skeletal Muscle AtrophyScience, 2001
- Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domainJournal of Molecular Biology, 2001
- Insulin-Like Growth Factor I Reduces Ubiquitin and Ubiquitin-Conjugating Enzyme Gene Expression but Does Not Inhibit Muscle Proteolysis in Septic RatsEndocrinology, 2000
- Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle.JCI Insight, 1994
- Different mechanisms of increased proteolysis in atrophy induced by denervation or unweighting of rat soleus muscleMetabolism, 1990